Abstract
In synucleinopathies, the protein α-synuclein misfolds into Lewy bodies (LBs) in patients with Lewy body disease (LBD) or into glial cytoplasmic inclusions (GCIs) in patients with multiple system atrophy (MSA). The ability of a single misfolded protein to cause disparate diseases is explained by the prion strain hypothesis, which argues that protein conformation is a major determinant of disease. We recently reported the unexpected finding of a novel α-synuclein strain in a Parkinson's disease with dementia patient sample containing GCI-like co-pathology along with widespread LB pathology, which led us to question if two α-synuclein strains can interact with one another in a patient and, if so, can strain competition occur. To test this possibility, we used the strain interference model developed in the prion field, in which a slower replicating strain-in this study, mouse-passaged MSA-is used to compete with a faster replicating strain-here, recombinant preformed fibrils (PFFs)-following sciatic nerve (sc.n.) inoculation. Unexpectedly, we found that PFFs generated using the same method differed in their ability to neuroinvade following sc.n. inoculation based on α-synuclein monomer source. Using a PFF preparation that does spread from the periphery, we conducted strain competition studies by first injecting TgM83(+/-) mice with mouse-passaged MSA into the sc.n. followed by a second injection with PFFs at 30, 45, and 60% of the MSA incubation period. We found that the two α-synuclein strains exhibited a synergistic effect during neuroinvasion, which was characterized by a decrease in incubation period along with evidence of the mouse-passaged MSA strain in the brain of terminal animals. These findings indicate that two α-synuclein strains can synergize with one another to accelerate the progression of clinical disease, representing a novel outcome in mixed infection studies.